Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ARTL
ARTL logo

ARTL Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Artelo Biosciences Inc (ARTL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.260
1 Day change
-0.79%
52 Week Range
85.800
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Artelo Biosciences Inc (ARTL) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive trading signals, weak technical indicators, absence of recent news, and no significant financial or congressional data make it a less compelling investment opportunity right now. Given the user's impatience and unwillingness to wait for optimal entry points, it's better to hold off on investing in this stock until stronger signals or catalysts emerge.

Technical Analysis

The MACD is positive but contracting, indicating weakening momentum. The RSI is in the neutral zone, showing no clear overbought or oversold conditions. Moving averages are bearish, with SMA_200 > SMA_20 > SMA_5, suggesting a downward trend. Key support is at 1.227, and resistance is at 1.402. Overall, the technical indicators do not suggest a strong buy opportunity.

Positive Catalysts

  • NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • Bearish moving averages and lack of upward momentum in technical indicators. No recent news or financial data to support a positive outlook.

Financial Performance

No financial data available for analysis due to an error in the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for evaluation.

Wall Street analysts forecast ARTL stock price to rise
Analyst Rating
0
Wall Street analysts forecast ARTL stock price to rise
Buy
Hold
Sell
0
Current: 1.270
sliders
Low
0
Averages
0
High
0
0
Current: 1.270
sliders
Low
0
Averages
0
High
0
D. Boral Capital
Jason Kolbert
Buy
to
Hold
downgrade
AI Analysis
2025-09-08
Reason
D. Boral Capital
Jason Kolbert
Price Target
AI Analysis
2025-09-08
downgrade
Buy
to
Hold
Reason
D. Boral Capital analyst Jason Kolbert downgraded Artelo Biosciences to Hold from Buy and removed the firm's prior price target following the company's "unexpected" $3M capital raise last week that came after what appeared to be an unsuccessful crypto-related strategy. Repeated attempts to reach management for clarification have been unsuccessful, notes the analyst, who cites the combination of "poor communication, a confusing strategic direction, and a dilutive capital raise" for the firm's more cautious stance.
D. Boral Capital
Hold
to
Buy
upgrade
$20
2025-07-08
Reason
D. Boral Capital
Price Target
$20
2025-07-08
upgrade
Hold
to
Buy
Reason
D. Boral Capital upgraded Artelo Biosciences (ARTL) to Buy from Hold with a $20 price target. The firm, which has adjusted its model and raised assumptions for the now completed reverse split, continues to view Artelo as an emerging biotechnology company focused on Cachexia and Chemotherapy-induced peripheral neuropathy with the lead program ART27.13, a Phase 2 asset acquired from Astra-Zenca (AZN), the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ARTL
Unlock Now

People Also Watch